Addex Therapeutics Ltd.
Close on Oct 19, 2026
About Addex Therapeutics
Pharmaceutical Preparations, SIC 2834
Addex Therapeutics Ltd. is a clinical-stage pharmaceutical company focused on discovering and developing orally available small molecule drug candidates. The company specializes in allosteric modulators targeting G-protein coupled receptors to treat conditions with high unmet medical needs. Its proprietary development pipeline includes dipraglurant for brain injury and post-stroke sensorimotor recovery, ADX71149 for evaluated neurological indications, and positive allosteric modulator programs targeting chronic cough and substance use disorders. Rather than selling directly to commercial consumers, the company advances candidates through internal programs or licenses them to pharmaceutical partners, such as Indivior.
The company operates internationally with its corporate headquarters and principal executive offices located in Geneva, Switzerland, alongside an additional investor contact office in the United States. Its operations include proprietary clinical and preclinical development programs supported by patent portfolios covering the United States, Europe, and Japan.
Summary of the business section of Addex Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Addex Therapeutics Ltd.
- Founded
- 2002
- Headquarters
- Geneva, V8
- Address
- Chemin Des Mines 9 CH-1202
- Phone
- 01141228841555
- Website
- addextherapeutics.com
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- V8
- Fiscal year ends
- December 31
- Auditor
- BDO AG, Zurich, Switzerland
Stock & identifiers
- Ticker
- ADXN
- Exchange
- Nasdaq
- IPO date
- Jan 28, 2020
- Shares outstanding
- 148M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-20 reverse, Oct 23, 2023
- SEC CIK
- 1574232
- CUSIP
- 00654J206
- ISIN
- US00654J2069
- LEI
- 89450068Y9KVP2MQGH86
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Roger Mills | CHIEF MEDICAL OFFICER, Director | 785,976 |
| Timothy Mark Dyer | CHIEF EXECUTIVE OFFICER, Director | 435,192 |
| Mikhail Kalinichev | HEAD OF TRANSLATIONAL SCIENCE | 0 |
| Lenaic Nathanael Teyssedou | PRINCIPAL ACCOUNTING OFFICER | – |
| Jason Raleigh Nunn | Director | 219,561 |
| Vincent Michael Lawton | Director | 2,507,987 |
| Raymond George Hill | Director | 0 |
| Isaac Manke | Director | 219,561 |
Employees
Headcount reported in annual reports
“We had 3 full-time employees as of December 31, 2025 compared to 2 at December 31, 2024.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | Late filing | Notification of late filing |
| Apr 30, 2025 | Late filing | Notification of late filing |
| Jan 28, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 14, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |